BioPharma Dive 6. März 2026 Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
BioPharma Dive 4. März 2026 FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
BioPharma Dive 3. März 2026 Pierre Fabre seeks to revive US approval chances for spurned cell therapy